Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01555346 · ClinicalTrials.gov registry record

Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

A clinical trial of Down Syndrome and Fetal Aneuploidy, sponsored by Sequenom.

Completed
Registry status
3,062
Enrollment target
20
Study locations

NCT01555346 is a study of Down Syndrome and Fetal Aneuploidy that has completed, run by Sequenom. The registered enrollment target is 3,062 participants, above the 2,415-participant average among 54 other Down Syndrome trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01555346, a study of Down Syndrome and Fetal Aneuploidy, has completed, sponsored by Sequenom.

COMPLETED
Registry status
3,062 participants
Enrollment target
20
Study locations

Study Summary

Whole blood samples will be collected from high-risk pregnant women to validate the clinical performance of the SEQureDx Trisomy 21 Test.

Study Locations (20)

California

  • Obstetrix Medical Group of California - Campbell
  • Long Beach Memorial Medical Center - Long Beach
  • Cedars-Sinai Medical Center - Los Angeles
  • San Gabriel Valley Perinatal Medical Center - Monterey Park
  • Scripps Clinic Carmel Valley - San Diego

Florida

  • South Florida Perinatal - Miami
  • Southeast Perinatal Associates - Miramar - Miramar
  • Southeast Perinatal Associates - Weston - Sunrise

New Jersey

  • Jersey Shore University Medical Center - Neptune City
  • Saint Peter's Hospital - New Brunswick

Alabama

  • University of South Alabama - Mobile

Arizona

  • Visions Clinical Research Tuscon - Tucson

Hawaii

  • Hawaii Pacific Health - Honolulu

Iowa

  • University of Iowa Health Care - Iowa City

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 3,062 participants
Start Date 2012-03
Est. Completion 2015-12

Sponsor

Sequenom

26 total trials

What the Registry Record Tells You About NCT01555346

The ClinicalTrials.gov registry entry for NCT01555346 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,062 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,415-participant average among 54 other Down Syndrome trials with a reported enrollment target (27% higher). The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Down Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT01555346 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New Jersey.

Frequently Asked Questions

What is clinical trial NCT01555346 about?

NCT01555346 is a clinical study titled "Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies". Whole blood samples will be collected from high-risk pregnant women to validate the clinical performance of the SEQureDx Trisomy 21 Test.

What is the current status of trial NCT01555346?

This trial is currently completed. The enrollment target is 3,062 participants. The study started on 2012-03. Estimated completion is 2015-12.

What conditions does trial NCT01555346 study?

This clinical trial studies the following conditions: Down Syndrome, Fetal Aneuploidy.

Who is sponsoring clinical trial NCT01555346?

This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01555346 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.